Clover Health Investments, Corp Form 4 Filings

Clover Health Investments, Corp. (CLOV) reported that Joseph Frank Oldakowski, its VP of Finance and Controller, sold 3,170 shares of Class A Common Stock on September 16, 2026 at $4.64 per share. After this transaction, he held 275,897 shares directly.

The filing explains that these shares were sold to cover tax withholding obligations arising from the vesting of 6.25% of restricted stock units (RSUs) granted on June 16, 2025, under Clover Health’s equity incentive plans. The remaining RSUs vest quarterly in equal 6.25% installments through a final vesting date of June 16, 2029, subject to his continued service. The company states these are mandatory "sell to cover" transactions under its plan and do not represent discretionary trades. The filing also affirms the use of a Rule 10b5-1 trading plan for these sales.

Clover Health Investments, Corp. (CLOV) reports that officer Wai Conrad, CEO of Counterpart Health, filed a Form 4 disclosing the sale of 300,000 shares of Class A common stock on September 15, 2026. The sale was executed at a weighted average price of $4.72 per share under a Rule 10b5-1 trading plan adopted on June 8, 2026, with individual trade prices ranging from $4.60 to $5.06. The shares sold were held indirectly in a family trust for which he serves as co-trustee; after the sale, that trust held 1,170,056 shares, and he also reported 1,065,699 shares held directly.

Clover Health Investments, Corp. (CLOV) reported that its Chief Legal Officer Karen Soares sold 6,846 shares of Class A common stock on September 15, 2026 at a weighted average price of $4.78 per share in sales mandated to cover tax withholding on the final vesting of 6.25% of restricted stock units granted September 15, 2022. These transactions were effected as a required "sell to cover" under the company’s equity incentive plans and are not discretionary trades; following the sale, Soares directly holds 1,607,371 shares of Class A common stock.

Clover Health Investments, Corp. (CLOV) reported that Jamie L. Reynoso, CEO, Medicare Advantage, sold 9,273 shares of Class A Common Stock on September 15, 2026 at a weighted average price of $4.78 per share. The footnotes state these mandated "sell to cover" transactions were executed under the issuer’s equity incentive plans to satisfy tax withholding on the vesting of the final 6.25% of restricted stock units originally granted on September 16, 2022 and do not represent discretionary trades. Following the sale, Reynoso directly holds 2,805,367 shares of Class A Common Stock.

Clover Health Investments (CLOV) reported that Joseph Frank Oldakowski, its VP of Finance and Controller, sold 20,000 shares of Class A Common Stock on September 14, 2026 at $5.16 per share in an open-market or private transaction. Following this sale, he continues to hold 279,067 shares directly.

Clover Health Investments, Corp. (CLOV) insider Joseph Clay, Interim CFO, reported selling 17,775 shares of Class A Common Stock on August 17, 2026 at a weighted average price of $4.39 per share. According to the company’s equity plan, this was a mandated “sell to cover” transaction to satisfy tax withholding obligations arising from the vesting of 6.25% of previously granted RSUs on August 16, 2026, and is described as non-discretionary. After the sale, Clay directly held 1,249,526 shares, and the remaining RSUs continue to vest quarterly in 6.25% increments through February 16, 2028, subject to continued service. The filing affirms that the transaction was effected under a Rule 10b5-1 trading plan.

Soares Karen reported acquisition or exercise transactions in this Form 4 filing.

Clover Health Investments, Corp. reported that Chief Legal Officer Karen Soares received a grant of 108,695 shares of Class A Common Stock in the form of time-based restricted stock units. The award vests 25% on the first anniversary of August 12, 2026, with the remainder vesting in twelve equal quarterly installments beginning three months after that anniversary, subject to her continued service, and brings her directly held shares to 1,614,217.

THORNTON JOSEPH CLAY reported acquisition or exercise transactions in this Form 4 filing.

Clover Health Investments reported that Interim CFO Joseph Clay Thornton received a grant of 54,347 shares of Class A Common Stock in the form of time-based restricted stock units (RSUs) on August 12, 2026. Twenty-five percent of these RSUs vest on the first anniversary of that date, with the remainder vesting in twelve equal quarterly installments until full vesting on August 12, 2030, subject to his continued service. Following this award, Thornton beneficially owns 1,267,301 shares of Class A Common Stock.

Clover Health Investments, Corp. director and Chief Executive Officer Andrew Toy reported a sale of 87,798 shares of Class A Common Stock on August 10, 2026 at a weighted average price of $4.65 per share. The shares were sold solely to cover tax withholding obligations tied to the final vesting on August 8, 2026 of 6.25% of restricted stock units granted on August 8, 2022, under a mandated "sell to cover" election, and are described as non‑discretionary transactions. Following this sale, Toy directly holds 9,459,316 shares of Class A Common Stock.

Clover Health Investments, Corp. Chief Legal Officer Karen Soares sold 51,700 shares of Class A Common Stock on July 20, 2026, reported as a sale in the open market or a private transaction at a $4.51 weighted average price, with individual prices from $4.46 to $4.59, pursuant to a 10b5-1 plan adopted on March 13, 2026. Following this sale, she directly holds 1,505,522 shares.

Clover Health Investments, Corp. executive Jamie L. Reynoso, CEO, Medicare Advantage, sold 4,839 shares of Class A Common Stock on July 17, 2026, at a $4.53 weighted average price, in multiple trades between $4.35 and $4.63 per share, under a Rule 10b5-1 trading plan adopted March 12, 2026. Following this sale, Reynoso directly holds 2,814,640 shares of Class A Common Stock.

Clover Health Investments CEO Andrew Toy reported a required sale of 62,711 Class A shares at a weighted average price of $4.67 per share to cover tax withholding from the vesting of 6.25% of RSUs originally granted on October 15, 2024. The company’s equity plan mandates these sell to cover trades, so they were not discretionary. After the sale, Toy directly holds 9,547,114 shares. Remaining RSUs vest in equal 6.25% quarterly installments through October 15, 2028, subject to continued service.

Clover Health Investments insider activity shows Wai Conrad, CEO of Counterpart Health, sold 24,215 Class A shares on July 15, 2026 at a weighted average $4.67, with prices from $4.67 to $4.73, solely to cover tax withholding on vesting of 6.25% of RSUs granted October 15, 2024. These mandated “sell to cover” trades under the company’s equity incentive plans are not discretionary. Afterward he held 1,145,699 shares directly and 1,390,056 shares indirectly through a family trust where he is co‑trustee, while the remaining RSUs vest quarterly in 6.25% installments through October 15, 2028.

Clover Health Investments, Corp. executive Jamie L. Reynoso reported an open-market sale of 13,119 shares of Class A Common Stock on July 15, 2026 at a weighted average price of $4.67 per share. The sale was a mandated "sell to cover" for tax withholding on RSU vesting and not a discretionary trade. Following the transaction, Reynoso holds 2,819,479 shares directly.

Clover Health Investments’ Chief Legal Officer Karen Soares reported an open-market sale of 10,519 shares of Class A common stock on July 15, 2026, at a weighted average price of $4.67 per share, within a $4.67–$4.73 range. According to the disclosure, the sale was mandated to cover tax withholding obligations arising from the vesting of restricted stock units granted on October 15, 2024, under the company’s equity incentive plans and does not represent a discretionary trade. After this tax-related sale, Soares continues to hold 1,557,222 shares directly. The remaining RSUs vest quarterly in 6.25% installments through October 15, 2028, subject to continued service.

Clover Health’s interim CFO, Joseph Clay, reported an open-market sale of 4,630 shares of Class A Common Stock on July 15, 2026 at a weighted average price of $4.67 per share. Footnotes state the sale was a mandated sell-to-cover transaction to satisfy tax withholding on the vesting of 6.25% of his restricted stock units granted on October 15, 2024. The RSUs continue to vest quarterly in 6.25% installments through October 15, 2028, subject to his continued service. Following the sale, he holds 1,212,954 shares directly.

Clover Health Investments, Corp. executive Jamie L. Reynoso, CEO of Medicare Advantage, reported an open-market sale of 2,384 shares of Class A Common Stock at $4.68 per share. After this transaction, Reynoso directly holds 2,832,598 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026, indicating it was scheduled in advance as part of a trading program rather than a discretionary one-time decision.

Clover Health Investments executive Jamie L. Reynoso, CEO of Medicare Advantage, reported an open-market sale of 6,229 shares of Class A Common Stock at $5.26 per share. After this transaction, Reynoso directly holds 2,834,982 shares.

According to the disclosure, the shares were sold solely to cover tax withholding obligations tied to the vesting of 6.25% of restricted stock units that vested on July 3, 2026. The RSUs were originally granted on January 3, 2023 and vest in equal 6.25% quarterly installments through a final vesting date on January 1, 2027, subject to continued service. The company states these sales are mandated under its equity incentive plans as “sell to cover” transactions and are not discretionary trades by Reynoso.

Clover Health Investments, Corp. Chief Executive Officer Andrew Toy reported an open-market sale of 313,476 shares of Class A common stock at $5.32 per share. According to the disclosure, these shares were sold solely to cover tax withholding obligations tied to the vesting of 6.25% of restricted stock units granted on January 1, 2023, under a mandatory “sell to cover” arrangement in the company’s equity incentive plans. Following the transaction, Toy directly owns 9,609,825 shares of Class A common stock. The remaining RSUs from this grant vest in equal 6.25% quarterly installments through January 1, 2027, contingent on continued service.

Clover Health Investments executive Jamie L. Reynoso, CEO of Medicare Advantage, sold 2,360 shares of Class A common stock in an open-market transaction at a weighted average price of $4.78 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026.

After this sale, Reynoso directly holds 2,841,211 Clover Health shares, so the transaction represents a very small portion of her overall stake.

Clover Health Investments vice president of finance and controller Joseph Frank Oldakowski reported an open-market sale of 12,102 shares of Class A Common Stock at $4.86 per share. After this transaction, he directly holds 299,067 shares.

According to the footnote, these shares were sold to cover tax withholding obligations tied to the vesting of 25% of restricted stock units granted on June 16, 2025. The remaining RSUs vest in equal 6.25% quarterly installments through June 16, 2029, subject to his continued service, and the sale is described as a mandatory “sell to cover” rather than a discretionary trade.

Clover Health Investments’ Chief Legal Officer Karen Soares reported a mandated share sale tied to tax withholding. She sold 4,681 shares of Class A common stock in open-market transactions at a weighted average price of about $4.61 per share, with trades ranging from $4.61 to $4.64.

The company’s equity incentive plan required these “sell to cover” transactions to satisfy tax obligations from vesting restricted stock units, so they were not discretionary trades. Following the sale, Soares directly holds 1,567,741 shares of Clover Health Class A common stock.

Clover Health Investments executive Jamie L. Reynoso, CEO of Medicare Advantage, reported a small sale of Class A common stock. On June 15, 2026, Reynoso sold 6,350 shares in open-market transactions at a weighted average price around $4.61 per share.

According to the disclosure, these shares were sold solely to cover tax withholding obligations triggered by the vesting of restricted stock units under the company’s equity incentive plans, and are described as non-discretionary “sell to cover” transactions. After this activity, Reynoso directly holds 2,843,571 shares of Clover Health Class A common stock.

Clover Health Investments executive Jamie L. Reynoso, CEO of Medicare Advantage, reported an open-market sale of Class A Common Stock. Reynoso sold 7,289 shares at a weighted average price of $4.91 per share under a pre-arranged Rule 10b5-1 trading plan. After this transaction, Reynoso directly holds 2,849,921 shares, so the sale represents a small portion of her overall position.

Wai Conrad, an officer of Clover Health Investments, reported an open-market sale of 220,426 shares of Class A Common Stock at an average price of $3.99 per share. The sale was effected under a Rule 10b5-1 trading plan adopted on March 3, 2025.

The shares were sold by a family trust for the benefit of his family, where he serves as co-trustee. Following these transactions, he holds 1,169,914 shares directly and 1,390,056 shares indirectly through the trust, so he continues to maintain a significant stake.

Clover Health Investments director Carladenise Armbrister Edwards reported an open-market sale of 67,160 shares of Class A Common Stock. The weighted average sale price was about $3.42 per share, with individual trades between $3.41 and $3.43. Following the sale, she directly holds 285,432 shares.

Clover Health Investments’ interim CFO Joseph Clay reported a routine tax-withholding transaction related to restricted stock units. On May 16, 2026, 16,942 shares of Class A Common Stock were automatically withheld at $3.47 per share to cover tax obligations from RSU vesting.

The withheld shares reflect 6.25% of the original RSU grant made on February 16, 2024. The remaining RSUs are scheduled to vest quarterly in equal 6.25% installments until February 16, 2028, subject to Joseph Clay’s continued service. After this transaction, he directly holds 1,217,584 Class A shares.

Clover Health Investments executive Brady Patrick Priest, CEO of Clover Care Services, reported an open-market sale of 98,039 shares of Class A common stock at $3.52 per share. After this transaction, he directly holds 2,040,222 shares, indicating he retains a substantial equity position.

Clover Health Investments Chief Executive Officer Andrew Toy reported a tax-related share withholding tied to vesting of previously granted equity. On May 8, 2026, 85,704 shares of Class A common stock were automatically withheld at $2.82 per share to cover tax obligations on vesting restricted stock units. After this disposition, Toy directly held 9,923,301 shares of Class A common stock. The underlying RSUs were part of a grant made on August 8, 2022, which vests in quarterly 6.25% installments through August 8, 2026, subject to his continued service.

Brady Patrick Priest, CEO of Clover Care Services, reported a routine tax-withholding transaction involving Clover Health Investments Class A Common Stock. On April 18, 2026, 36,113 shares were automatically withheld at $2.19 per share to cover tax obligations tied to restricted stock unit vesting.

The withheld shares relate to 6.25% of a time-based RSU grant originally awarded on July 18, 2022. The remaining RSUs from this grant vest in equal 6.25% quarterly installments through July 18, 2026, as long as Priest continues in service. After this withholding, he directly holds 2,138,261 shares of Class A Common Stock. This event reflects compensation-related tax settlement rather than an open-market sale.

Clover Health Investments executive Brady Patrick Priest, CEO of Clover Care Services, reported an automatic tax-withholding share disposition tied to vesting RSUs. On April 15, 2026, 15,471 shares of Class A Common Stock were withheld at $2.04 per share to cover tax obligations, not sold on the open market.

The withheld shares relate to 6.25% of the original RSU grant awarded on October 15, 2024. Following this routine tax-withholding event, Priest directly holds 2,174,374 Class A shares. The remaining RSUs are scheduled to vest in equal 6.25% quarterly installments through October 15, 2028, contingent on continued service.

Clover Health Investments’ Chief Legal Officer, Karen Soares, reported a routine tax-related share withholding linked to restricted stock units (RSUs). On April 15, 2026, 10,161 shares of Class A Common Stock were automatically withheld at $2.04 per share to cover tax obligations when 6.25% of a previously granted RSU award vested.

After this tax-withholding disposition, Soares directly holds 1,572,422 shares of Clover Health Class A Common Stock. The RSU grant from October 15, 2024 continues to vest quarterly in equal 6.25% installments through October 15, 2028, as long as she remains in service.

Clover Health Investments CEO Andrew Toy reported a routine tax-related share disposition. On April 15, 2026, 60,765 shares of Class A Common Stock were automatically withheld at $2.04 per share to cover tax obligations from RSU vesting. After this withholding, Toy directly owned 10,009,005 shares.

The withheld shares relate to 6.25% of an RSU grant originally awarded on October 15, 2024. The remaining RSUs are scheduled to vest in equal 6.25% quarterly installments through October 15, 2028, contingent on Toy’s continued service.

Clover Health Investments' Interim CFO, Joseph Clay, reported a routine tax-withholding event tied to restricted stock units. On April 15, 2026, 4,158 shares of Class A Common Stock were automatically withheld at $2.04 per share to cover taxes when 6.25% of an RSU grant vested.

The RSUs were originally granted on October 15, 2024 and continue to vest in equal 6.25% quarterly installments through October 15, 2028, as long as Clay remains in service. After this non-market tax-withholding disposition, he directly holds 1,234,526 shares of Class A Common Stock.

Clover Health Investments executive Jamie L. Reynoso reported an automatic share disposition tied to equity compensation. On April 15, 2026, 12,712 shares of Class A Common Stock were withheld at $2.04 per share to cover tax obligations from vesting restricted stock units (RSUs). After this tax-withholding event, Reynoso directly holds 2,857,210 shares of Class A Common Stock. The footnote explains that this reflects 6.25% of an RSU grant made on October 15, 2024, with the remaining RSUs scheduled to vest in equal 6.25% quarterly installments through October 15, 2028, contingent on continued service.

Clover Health Investments, Corp. reported an insider equity event involving executive Conrad Wai. On April 15, 2026, 23,463 shares of Class A Common Stock were automatically withheld at $2.04 per share to cover tax obligations arising from the vesting of restricted stock units granted in October 2024.

The vested portion represented 6.25% of the original RSU grant, with additional 6.25% installments scheduled to vest quarterly through October 15, 2028, subject to continued service. Following this tax-withholding disposition, Wai holds 1,169,914 shares directly and 1,610,482 shares indirectly through a family trust where he is co-trustee.

Clover Health Investments executive Jamie L. Reynoso, CEO, Medicare Advantage, had 6,197 shares of Class A Common Stock withheld on April 3, 2026 to cover tax obligations. The withholding related to the vesting of 6.25% of restricted stock units granted on January 3, 2023.

After this tax-withholding disposition, Reynoso directly holds 2,869,922 shares of Class A Common Stock. The remaining RSUs from the 2023 grant will vest in equal quarterly installments through January 3, 2027, subject to Reynoso’s continued service on each vesting date.

Priest Brady Patrick reported acquisition or exercise transactions in this Form 4 filing.

Clover Health Investments insider Brady Patrick Priest, CEO of Clover Care Services, received an award of 191,261 shares of Class A Common Stock in the form of time-based restricted stock units. These RSUs were granted at no cash purchase price as part of his equity compensation.

After this award, Priest directly holds 2,189,845 shares of Class A Common Stock. Twenty-five percent of the RSUs will vest on the first anniversary of April 1, 2026, and the remaining units will vest in twelve equal quarterly installments, becoming fully vested on April 1, 2030, assuming his continued service.

Reynoso Jamie L. reported acquisition or exercise transactions in this Form 4 filing.

Clover Health Investments reported that Jamie L. Reynoso, CEO of Medicare Advantage, received a grant of 159,384 shares of Class A common stock in the form of time-based restricted stock units. These RSUs were awarded at no cash cost per share as equity compensation.

According to the grant terms, 25% of the RSUs will vest on the first anniversary of April 1, 2026. The remaining units will vest in twelve equal quarterly installments starting three months after that first anniversary, so that all RSUs are fully vested by April 1, 2030, subject to continued service. Following this award, Reynoso directly holds 2,876,119 shares of Class A common stock.

Clover Health Investments Chief Executive Officer Andrew Toy reported equity compensation changes involving Class A Common Stock. He received a grant of 956,307 shares underlying time-based restricted stock units, with 25% vesting on the first anniversary of April 1, 2026 and the remainder vesting in 12 equal quarterly installments until April 1, 2030, subject to continued service. On the same date, 309,558 shares were automatically withheld at $1.76 per share to cover tax obligations from the vesting of earlier RSUs granted January 1, 2023. After these transactions, he directly holds 10,069,770 shares of Class A Common Stock.

Wai Conrad reported acquisition or exercise transactions in this Form 4 filing.

Clover Health Investments reported that executive Wai Conrad, CEO of Counterpart Health, received a grant of 267,766 shares of Class A common stock in the form of time-based restricted stock units. The award was granted at $0.00 per share, reflecting a compensation grant rather than a market purchase.

According to the vesting schedule, 25% of these RSUs will vest on the first anniversary of April 1, 2026, with the remaining units vesting in twelve equal quarterly installments beginning three months after that first anniversary, so that all RSUs are fully vested on April 1, 2030, subject to Mr. Conrad’s continued service. Following this grant, he holds 1,193,377 shares directly, and a family trust, for which he is a co-trustee, holds 1,610,482 shares indirectly.

Soares Karen reported acquisition or exercise transactions in this Form 4 filing.

Clover Health Investments Chief Legal Officer Karen Soares received a grant of 382,522 shares of Class A common stock in the form of time-based restricted stock units. These RSUs were awarded at no cash cost and increase her direct ownership to 1,582,583 shares after the grant.

Twenty-five percent of the RSUs will vest on the first anniversary of April 1, 2026. The remaining units will then vest in twelve equal quarterly installments beginning three months after that first anniversary, with all RSUs fully vested on April 1, 2030, assuming she continues in service through each vesting date.

Clover Health Investments executive Jamie L. Reynoso, CEO, Medicare Advantage, sold 5,833 shares of Class A common stock in an open-market transaction at a weighted average price of $1.91 per share. The shares were sold in multiple trades between $1.87 and $1.96 per share pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2025. After this sale, Reynoso directly holds 2,716,735 Class A shares.

Clover Health Investments executive Jamie L. Reynoso reported automatic share withholdings to cover tax obligations tied to restricted stock units that vested on March 14 and 15, 2026. On March 14, 6,945 shares of Class A Common Stock were withheld at $1.98 per share, followed by 6,187 shares on March 15 at the same price. These are coded as tax-withholding dispositions rather than open-market sales. After the March 15 withholding, Reynoso directly holds 2,722,568 Class A shares.

The March 14 withholding relates to the final 6.25% vesting of time-based RSUs granted on March 14, 2022. The March 15 withholding relates to 6.25% of RSUs granted on September 16, 2022, which continue to vest quarterly in 6.25% installments through a final vesting date on September 15, 2026, subject to Reynoso’s continued service.

Clover Health Investments reported a routine tax-related share withholding by its General Counsel and Secretary, Karen Soares. On March 15, 2026, 4,528 shares of Class A common stock were automatically withheld to cover taxes when 6.25% of her September 15, 2022 time-based RSU grant vested. The remaining RSUs vest quarterly in 6.25% installments through September 15, 2026, subject to her continued service. After this withholding, she directly held 1,200,061 shares of Class A common stock.

Clover Health Investments, Corp. insider Conrad Wai, CEO of Counterpart Health, reported a routine tax-related share withholding. On March 14, 2026, 100,195 shares of Class A Common Stock were automatically withheld to cover tax obligations when the final 6.25% of his time-based RSUs granted on March 14, 2022 vested.

Following this tax-withholding disposition, Wai directly holds 925,611 shares of Class A Common Stock. He also has an indirect position of 1,610,482 shares held in a trust for his family's benefit, where he serves as co-trustee. The filing reflects compensation-related mechanics rather than an open-market sale.

Clover Health Investments executive Brady Patrick Priest, CEO of Home Care, reported an open-market sale of Class A Common Stock. On March 4, 2026, he sold 175,000 shares at a weighted average price of $2.17 per share, in multiple trades between $2.16 and $2.18.

After this transaction, Priest held 1,998,584 shares of Clover Health Class A Common Stock in direct ownership.

Clover Health Investments General Counsel & Secretary Karen Soares reported a tax-related share disposition. On February 14, 2026, 6,090 shares of Class A common stock were automatically withheld at $2.02 per share to cover tax obligations upon vesting of restricted stock units granted on February 14, 2022. After this withholding, she directly owned 1,204,589 Class A shares.

Clover Health Investments’ Chief Executive Officer and director Andrew Toy reported an automatic share withholding tied to restricted stock unit (RSU) vesting. On February 8, 2026, 85,704 shares of Class A common stock were withheld at $2.13 per share to cover tax obligations arising from the vesting of 6.25% of his original time-based RSU grant from August 8, 2022. After this tax withholding, Toy beneficially owned 9,423,021 shares of Class A common stock directly. The remaining RSUs from the 2022 grant are scheduled to vest quarterly in equal 6.25% installments through August 8, 2026, subject to his continued service.